Success Metrics

Clinical Success Rate
67.9%

Based on 114 completed trials

Completion Rate
68%(114/168)
Active Trials
31(11%)
Results Posted
59%(67 trials)
Terminated
54(19%)

Phase Distribution

Ph early_phase_1
6
2%
Ph phase_2
87
31%
Ph not_applicable
22
8%
Ph phase_4
35
13%
Ph phase_3
61
22%
Ph phase_1
51
18%

Phase Distribution

57

Early Stage

87

Mid Stage

96

Late Stage

Phase Distribution262 total trials
Early Phase 1First-in-human
6(2.3%)
Phase 1Safety & dosage
51(19.5%)
Phase 2Efficacy & side effects
87(33.2%)
Phase 3Large-scale testing
61(23.3%)
Phase 4Post-market surveillance
35(13.4%)
N/ANon-phased studies
22(8.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

59.7%

114 of 191 finished

Non-Completion Rate

40.3%

77 ended early

Currently Active

31

trials recruiting

Total Trials

277

all time

Status Distribution
Active(33)
Completed(114)
Terminated(77)
Other(53)

Detailed Status

Completed114
Terminated54
unknown49
Withdrawn23
Recruiting21
Active, not recruiting10

Development Timeline

Analytics

Development Status

Total Trials
277
Active
31
Success Rate
67.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (2.3%)
Phase 151 (19.5%)
Phase 287 (33.2%)
Phase 361 (23.3%)
Phase 435 (13.4%)
N/A22 (8.4%)

Trials by Status

suspended41%
unknown4918%
active_not_recruiting104%
recruiting218%
withdrawn238%
terminated5419%
not_yet_recruiting21%
completed11441%

Recent Activity

31 active trials
Showing 5 of 277
terminatedphase_2

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
completedphase_2

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

NCT01494155
recruitingphase_3

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT05799378
completedphase_2

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

NCT04669197
recruitingphase_2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View all 277 trials

Clinical Trials (277)

Showing 20 of 277 trialsScroll for more
NCT04527549Phase 2

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Terminated
NCT01494155Phase 2

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

Completed
NCT05799378Phase 3

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Recruiting
NCT04669197Phase 2

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

Completed
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting
NCT04315948Phase 3

Trial of Treatments for COVID-19 in Hospitalized Adults

Completed
NCT03032406Phase 2

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Active Not Recruiting
NCT05843188Phase 2

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

Active Not Recruiting
NCT03414502Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
NCT04464759Phase 1

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Active Not Recruiting
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT04523857Phase 2

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

Recruiting
NCT05110651Phase 4

The Danish Pre-HCQ COVID Dialysis Study

Withdrawn
NCT03825289Phase 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Terminated
NCT03598595Phase 1

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active Not Recruiting
NCT04316494Phase 4

Hydroxychloroquine in ANCA Vasculitis Evaluation

Terminated
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT05842174Phase 1

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Recruiting
NCT02595346Phase 2

Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome

Terminated
NCT01480154Phase 1

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
277